||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


MediGene to be Listed on TecDAX Index

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------




Martinsried/Munich, February 5, 2009. The biotech company MediGene AG
(Frankfurt, Prime Standard: MDG) has been selected for inclusion on
the TecDAX, an index of the Frankfurt Stock Exchange including
Germany's most important mid-cap technology companies. The TecDAX
follows the blue chip DAX index and comprises 30 companies admitted
to the stock market "Prime Standard" segment. In addition to
compliance with comprehensive international transparency
requirements, the admission criteria include an above-average market
capitalization (share price multiplied by the number of company
shares), and a high trading volume (number of shares traded daily).
According to the decision made by the German Stock Exchange on
February 5, 2009, MediGene has fulfilled the admission criteria for
the TecDAX and will be included there as of February 09, 2009.

Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, comments:
"TecDAX membership signifies MediGene's position among the leading
German technology securities. This admission is a reflection of
MediGene's dynamic growth and achievement in the biotechnology
sector. The TecDAX listing increases MediGene's visibility in the
capital markets and facilitates our collaboration with domestic and
international investors."


This press release contains forward-looking statements representing
the opinion of MediGene as of the date of this release. The actual
results achieved by MediGene may differ significantly from the
statements made herein. MediGene is not bound to update any of these
forward-looking statements. MediGene® is a registered trademark of
MediGene AG. This trademark may be owned or licensed in select
locations only.


- ends -


MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG)
biotechnology company located in Martinsried/Munich, Germany, with
subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first
German biotech company to have drugs on the market, which are being
distributed by partner companies and has several drug candidates in
clinical development, two of which provide significant sales
potential. In addition, the company has numerous projects in research
and pre-clinical development and possesses innovative platform
technologies. MediGene focuses on the research and development of
novel drugs for the treatment of cancer and autoimmune diseases.

Contact MediGene AG
E-mail: investor@medigene.com
Fax: +49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: +49 - 89 - 85
65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: +49 - 89 - 85 65 - 2946



--- End of Message ---

MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN:
502090; ISIN: DE0005020903 ;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Regulierter Markt in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.



 
 ||| Themen-Infos 
· Mehr zu dem Thema Contracts & Corporate events & IPOs &

Der meistgelesene Artikel zu dem Thema Contracts & Corporate events & IPOs &:
Change on the Board of Directors of Feintool Holding AG

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.100 Sekunden